TABLE 3.

In vivo activities of MXF, GAT, LVX, and CLR alone and FQ-CLR combinations against MAC-infected mice

StrainAgentLog10 CFU/organa
LungsLiverSpleen
M. avium JATA51-01 (indifferent)Control9.16 ± 0.06c10.15 ± 0.079.58 ± 0.08
MXF8.83 ± 0.18b9.68 ± 0.05b,c9.18 ± 0.08b,c
GAT8.90 ± 0.14c9.91 ± 0.05b,c9.18 ± 0.08b,c
LVX9.01 ± 0.09c9.92 ± 0.07b,c9.38 ± 0.13b,c
CLR7.10 ± 0.08b8.12 ± 0.11b7.10 ± 0.09b
MXF + CLR7.48 ± 0.10b8.13 ± 0.09b7.41 ± 0.04b
GAT + CLR7.10 ± 0.18b8.08 ± 0.07b7.27 ± 0.12b
LVX + CLR7.10 ± 0.19b8.12 ± 0.06b6.97 ± 0.09b
M. intracellulare JATA52-01 (antagonistic)Control5.51 ± 0.125.51 ± 0.064.60 ± 0.16
MXF4.83 ± 0.17b,c4.76 ± 0.12b,c4.15 ± 0.10b,c
GAT5.32 ± 0.16c5.15 ± 0.06b,c4.41 ± 0.11c
LVX5.47 ± 0.08c5.16 ± 0.11b,c4.48 ± 0.12c
CLR3.17 ± 0.07b3.20 ± 0.04b3.16 ± 0.12b
MXF + CLR3.23 ± 0.08b3.59 ± 0.05b,c3.42 ± 0.08b
GAT + CLR3.43 ± 0.02b3.65 ± 0.06b,c3.46 ± 0.06b,c
LVX + CLR3.36 ± 0.07b3.39 ± 0.05b3.32 ± 0.05b
MAC N016 (indifferent)Control6.61 ± 0.157.64 ± 0.077.61 ± 0.10
MXF5.35 ± 0.10b,c6.53 ± 0.08b,c6.60 ± 0.14b,c
GAT5.48 ± 0.11b,c6.60 ± 0.11b,c6.81 ± 0.09b,c
LVX5.48 ± 0.09b,c6.52 ± 0.10b,c6.72 ± 0.16b,c
CLR3.94 ± 0.21b5.91 ± 0.02b5.36 ± 0.11b
MXF + CLR4.17 ± 0.11b5.78 ± 0.03b5.57 ± 0.06b
GAT + CLR3.96 ± 0.06b5.72 ± 0.06b5.35 ± 0.11b
LVX + CLR4.25 ± 0.21b5.86 ± 0.21b5.57 ± 0.06b
MAC N018 (antagonistic)Control6.40 ± 0.057.63 ± 0.067.40 ± 0.04
MXF5.79 ± 0.06b,c7.09 ± 0.05b,c6.60 ± 0.08b,c
GAT5.96 ± 0.08b,c7.21 ± 0.06b,c6.75 ± 0.10b,c
LVX6.01 ± 0.04b,c7.40 ± 0.05b,c6.82 ± 0.04b,c
CLR2.18 ± 0.09b5.03 ± 0.08b4.06 ± 0.10b
MXF + CLR3.05 ± 0.18b,c5.37 ± 0.07b,c4.26 ± 0.14b
GAT + CLR3.11 ± 0.12b,c5.25 ± 0.09b,c4.34 ± 0.13b
LVX + CLR2.37 ± 0.13b5.39 ± 0.05b,c4.32 ± 0.09b,c
MAC N084 (antagonistic)Control8.13 ± 0.168.17 ± 0.078.04 ± 0.11
MXF7.90 ± 0.06c7.78 ± 0.07b,c7.39 ± 0.10b,c
GAT8.14 ± 0.07c8.00 ± 0.08c7.60 ± 0.08b,c
LVX7.82 ± 0.07c7.77 ± 0.09b,c7.58 ± 0.13b,c
CLR5.28 ± 0.11b4.58 ± 0.06b4.30 ± 0.11b
MXF + CLR5.68 ± 0.08b,c5.47 ± 0.15b,c4.90 ± 0.09b,c
GAT + CLR5.54 ± 0.08b,c5.29 ± 0.11b4.72 ± 0.12b,c
LVX + CLR5.24 ± 0.08b5.08 ± 0.15b,c4.60 ± 0.12b,c
  • a Activities of CLR (200 mg/kg/day), MXF (100 mg/kg/day), GAT (100 mg/kg/day), LVX (200 mg/kg/day), and FQ-CLR combinations against MAC-infected mice. Viable bacterial counts were determined in the lungs, liver, and spleen 48 h after completion of therapy. A total of five mice were examined per group, and each value represents the mean ± standard error of the mean. Significant differences (P < 0.05) in viable bacterial numbers between treatments with each FQ alone and with FQ-CLR combinations (e.g., MXF versus MXF-CLR) were obtained for all target organs. The experiment was performed twice, and the data shown are from the second experiment. Similar results and statistical tendencies were obtained from the first experiment.

  • b P < 0.05 versus control mice as evaluated by Fisher's protected least significant difference test after analysis of variance.

  • c P < 0.05 versus CLR alone as evaluated by Fisher's protected least significant difference test after analysis of variance.